Barclays raised the firm’s price target on Grifols to EUR 11.50 from EUR 10 and keeps an Equal Weight rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on GRFS:
- GRFS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Grifols Achieves Positive Topline Results From Phase 4 Study of XEMBIFY® (immune globulin subcutaneous human-klhw) Evaluating Biweekly Dosing Option for Patients
- Grifols announces its Phase 4 trial of XEMBIFY met its primary endpoint
- Grifols completes enrollment in Phase 3 study of long-term Albutein
- Grifols Completes Enrollment in Phase 3 Study of Long-term Albutein® (albumin-human injection) Therapy for Patients with Decompensated Cirrhosis